article thumbnail

Magazine: The GLP-1 shortage is over. What’s next for compounders?

Pharmaceutical Technology

The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisks semaglutide (Wegovy/Ozempic) and Eli Lillys tirzepatide (Mounjaro/Zepbound).

article thumbnail

Rising Demand for Customized Medication To Transform Compounding Pharmacies Market Outlook

Pharma Mirror

Compounding pharmacies, which involve the preparation and selling of prescribed medicines are gaining massive popularity across the healthcare sector owing to the rising awareness regarding the benefits of compounded medications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

PCR Buffer: Polymerase Chain Reaction Mediator

Pharma Mirror

A PCR buffer is a mixture of compounds that creates a suitable environment for the polymerase chain reaction. The post PCR Buffer: Polymerase Chain Reaction Mediator appeared first on Pharma Mirror Magazine. You know that DNA making is a life process, and it needs an environment similar to the cell’s internal conditions.

article thumbnail

Catalent Signs Commercial Supply Agreement with Phathom

Pharma Mirror

The post Catalent Signs Commercial Supply Agreement with Phathom appeared first on Pharma Mirror Magazine. P-CABs are a new class of medicines that block acid secretion in the stomach.

article thumbnail

Hitachi, Tohoku University and Kyoto University Become World’s First to Establish Technology for Highly Efficient Production of Actinium-225

Pharma Mirror

TAT is a new cancer therapy which combines a substance that emits alpha particles which destroy cancer cells with a compound that selectively accumulates in cancer cells. The combined alpha-emitting agent is administered to a patient to attack cancer cells within the body (Figure 1). It is known to be effective against forms of cancers that.

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Can pharma tariffs “Make America Manufacture Again”?